Trial Profile
Belimumab for the treatment of frequently relapsing nephrotic syndrome open label phase II trial. BELNEPH STUDY
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Nephrotic syndrome
- Focus Adverse reactions
- Acronyms BELNEPH
- 01 Feb 2022 Status changed to discontinued, because belimumab failed to show clear benefits to counterbalance the inconvenience of monthly i.v. infusion as per results published in the Pediatric Nephrology
- 12 Mar 2018 New trial record